Manganese MRI to image heart changes after takotsubo (broken heart) cardiomyopathy
Official title: Manganese-enhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy
Run by University of Edinburgh · NCT07491718 · Data updated 2026-11-12
This project will test whether manganese-enhanced cardiac MRI, together with common heart medications, can reveal ongoing heart muscle changes in adults with takotsubo (broken heart) cardiomyopathy.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | University of Edinburgh Academic / other |
| Locations | 1 site (Edinburgh) |
| Status | Recruiting |
| Started | August 8, 2025 |
| Main results expected | August 9, 2028 |
| Study ends | August 9, 2028 |
| Registry record updated | September 18, 2026 |
| Trial ID | NCT07491718 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with a clinical diagnosis of takotsubo cardiomyopathy who can give informed consent, including those diagnosed within the past 3 months or more than 6 months ago, are the intended participants.
✕Probably not a fit
People who cannot undergo MRI, have severe renal failure, are pregnant, have prior cardiomyopathy, are on digoxin, or have contraindications to the study drugs (for example type 1 diabetes for dapagliflozin or severe asthma for bisoprolol) are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Researchers will use manganese-enhanced cardiac MRI to measure manganese uptake in the heart as a marker of cellular-level changes after takotsubo cardiomyopathy. Participants are grouped by time since diagnosis: those diagnosed under 3 months may receive bisoprolol, valsartan, or no medication, while those diagnosed over 6 months may receive sacubitril/valsartan or dapagliflozin for three months. MRI scans and clinical tests will be compared before and after the medication period to see if drug treatment changes manganese uptake. The study aims to link commonly used heart medications with persistent imaging abnormalities following takotsubo.
Why it matters
Potential benefit: If successful, this approach could identify lingering heart muscle abnormalities after takotsubo and help guide use of existing heart medications to improve long-term outcomes.
How similar studies have gone: Previous work at the University of Edinburgh has shown manganese-enhanced MRI detects persistent changes after takotsubo, but using standard heart failure medications to modify those imaging findings is largely novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Males and females \>18 years of age * Clinical presentation of takotsubo cardiomyopathy * Have capacity to give formal consent Exclusion Criteria: * Unable to tolerate or contraindication to magnetic resonance imaging * Renal failure (estimated glomerular filtration rate \<30 mL/min/1.73 m2) - this would be assessed by performing a blood test * Prior history of cardiomyopathy * Current pregnancy * Weight greater than 250kg * Severe asthma for study 1 (given Bisoprolol is contraindicated in this condition) * Type 1 diabetes mellitus for study 2 (given Dapaglifozin is contraindicated in this population) * Significant hypotension (given the medications prescribed as part of the study can also cause hypotension as a side effect) * Significant bradycardia for study 1 (given Bisoprolol can exacerbate any pre-existing significant bradycardia) * Prescribed Digoxin (this medication interacts with the Manganese) * Unable to give formal consent
Where it's running
-
University of Edinburgh
Edinburgh, United Kingdom Recruiting
Study contacts
- Study coordinator: Jennifer Ramsay
- Email: jramsay5@ed.ac.uk
- Phone: 01316501000
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Investigating heart issues in COPD patients during hospital stays
This study is trying to see if sudden worsening of COPD can cause heart problems in hospitalized patients and how it affects their recovery.
-
Resilience training for patients with heart disease
This study tests a resilience training program to see if it helps heart disease patients cope better with stress and improve their overall quality of life.
-
Using cardiac imaging to improve risk assessment in Takotsubo syndrome
This study is testing a new way to predict how well patients with Takotsubo syndrome will do in the hospital and over time by using heart imaging and comparing it to current methods.
-
Virtual support group for patients with Takotsubo syndrome
This study is testing if joining a virtual support group can help adults with Takotsubo syndrome feel less anxious after a year.
-
Using Cyclosporine to treat Takotsubo Syndrome
This study is testing if a medication called Cyclosporine can help people with Takotsubo syndrome recover better and have less heart damage compared to those who get a placebo.
-
Investigating genetic factors in Takotsubo cardiomyopathy
This study is trying to see if certain genes make some people more likely to develop broken heart syndrome after experiencing acute stress.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.